Meeting
2023 ASCO Annual Meeting
The prognostic value of patient reported outcomes (PROs) and clinical/demographic variables in the CASPIAN study.
Authors
Apar Kishor Ganti
University of Nebraska Medical Center, Omaha, NE
Apar Kishor Ganti , Sukhvinder Johal , Daniel Jackson , Nenad Medic , Kieran Davey , Lance Brannman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03043872
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8516)
DOI
10.1200/JCO.2023.41.16_suppl.8516
Abstract #
8516
Poster Bd #
143
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
First Author: Bruno Sangro
Poster
2016 ASCO Annual Meeting
Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).
First Author: George D. Demetri
Poster
2024 ASCO Annual Meeting
Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).
First Author: Vania Hungria
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ADJUBIL: A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer.
First Author: Thorsten Goetze